Two new studies have revealed that gut microbes known as fusobacteria, which are found in the mouth, stimulate bad immune responses and turn on cancer growth genes to generate colorectal tumors.
The findings could lead to more effective strategies for the early diagnosis, prevention, and treatment of colorectal cancer.
"Fusobacteria may provide not only a new way to group or describe colon cancers but also, more importantly, a new perspective on how to target pathways to halt tumor growth and spread," senior study author Wendy Garrett of the Harvard School of Public Health and the Dana-Farber Cancer Institute, said.
Colorectal cancer is the second leading cause of cancer-related death in the United States.
Recent studies have shown that fusobacteria from the mouth are also abundant in tissues from colorectal cancer patients. But until now, it was not known whether these microbes directly contribute to the formation of tumors.
In one of the new studies, Garrett, Matthew Meyerson of the Dana-Farber Cancer Institute, and their collaborators found that fusobacteria are prevalent in human adenomas-benign tumors that can become malignant over time-suggesting that these microbes contribute to early stages of tumor formation.
In a mouse model of colorectal cancer, these bacteria accelerated the formation of tumors by attracting immune cells called myeloid cells, which invade tumors and stimulate inflammatory responses that can cause cancer.
In the second study, Yiping Han of Case Western Reserve University School of Dental Medicine and her collaborators discovered that fusobacteria rely on a molecule called Fusobacterium adhesin A (FadA), which is found on the surface of these bacterial cells, to attach to and invade human colorectal cancer cells.
FadA then turns on cancer growth genes and stimulates inflammatory responses in these cells and promotes tumor formation.
Han and her team also found that FadA levels were much higher in tissues from patients with adenomas and colorectal cancer compared with healthy individuals.
Moreover, they identified a compound that can prevent FadA's effects on cancer cells.
The study is published in the journal Cell Host and Microbe.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
